patient

Jan P. Bewersdorf, MD

Bewersdorf, Jan

Assistant Professor of Medicine

Yale School of Medicine

Jan Philipp Bewersdorf, MD, specializes in hematology with a focus on the treatment of myeloid malignancies, including myeloproliferative neoplasms,

Online Profile:

https://www.ynhh.org/physicians/jan-p-bewersdorf

2025 EHA Update: Aplastic Anemia and PNH

In this webinar, Dr. Phillip Scheinberg will discuss the latest research presented at EHA about

2025 EHA/ASCO Update: MDS and AML

In this webinar, Dr. Jan Bewersdorf discusses the latest research presented at EHA and ASCO on MDS and AML. This is an advanced presentation.

MDS - MPN Overlap from the 2025 Chapel Hill Patient and Family Conference

In this recording, Dr. Lacey Williams discusses the diagnosis of MDS/MPN overlap and the treatment options available to patients.

A Patient Story: Shauna McMillian - from the 2025 Chapel Hill Patient and Family Conference

Shauna describes her journey with MDS, or Myelodsplastic Syndromes, in this recorded session from the 2025 Chapel Hill Patient and Family Conference.

Managing PNH Complications from the Chapel Hill Patient and Family Conference

In this recording, Dr. Srinivasa Sanikommu discusses complications that can occur during a PNH patient's lifetime and the treatment options available to patients.

Transplant and GVHD from the 2025 Chapel Hill Patient and Family Conference

In this recording, Dr. Jeremy Meier discusses the journey of a transplant (before, during and after) and potential management of GVHD.

Aplastic Anemia from the 2025 Chapel Hill Patient and Family Conference

In this recording, Dr. Brandi Reeves discusses the diagnosis of

A 30-gene classifier distinguishes low-risk MDS HSPCs from healthy HSPCs

Highlights
•
Single-cell RNA-sequencing performed on 16 lower-risk myelodysplastic syndrome (LR-MDS) bone marrow-derived mononuclear cells (BMMCs)
•
A 30-gene signature distinguishes LR-MDS hematopoietic stem and progenitor cells (HSPCs) from Healthy HSPCs
•
Vesicular trafficking-related gene modules are enriched in MDS
•

Cyclophosphamide and Cyclosporin for GVHD Prevention

Curtis et al. (July 17 issue)1 report evidence of longer graft-versus-host disease (GVHD)–free, relapse-free survival with post-transplantation cyclophosphamide–based prophylaxis than with cyclosporin–methotrexate among patients receiving a stem-cell transplant from a matched related donor after myeloablative conditioning or reduced-intensity conditioning.